LifeArc

Tribune Therapeutics is a preclinical biopharmaceutical company dedicated to advancing novel therapies for fibrotic diseases. They focus on developing innovative medicines targeting the CCN protein family, which plays a crucial role in fibrosis development. Their pipeline aims to address a broad spectrum of fibrotic conditions, offering potential new treatment options for patients.

Hillstar Bio is a biopharmaceutical company focused on developing precision immunotherapies for treating autoimmune diseases. Its innovative approach selectively targets and depletes harmful immune cells, sparing healthy ones, to address specific disease mechanisms and reduce the risks associated with chronic broad immunosuppression. The company aims to provide durable relief and immune reset for patients with autoimmune conditions, addressing unmet medical needs.

Maxion Therapeutics is a biopharmaceutical company focused on developing innovative therapies for diseases driven by ion channels and G protein-coupled receptors (GPCRs). The company utilizes a unique drug discovery platform that integrates ion channel-modulating mini-proteins, known as knottins, derived from venom and other natural sources. By combining these knottins with antibody frameworks, Maxion aims to create long-acting, safe, and effective therapeutics that address previously inaccessible medical targets. This approach enables the potential treatment of various conditions, including chronic pain, autoimmune disorders, and heart disease, ultimately enhancing patient care through advanced drug development.

Fluid Biomed is a medical device start-up specializing in the development of an innovative implantable dissolving stent aimed at treating brain aneurysms. Founded by a team of neurosurgeons, the company focuses on enhancing patient outcomes by offering a bio-absorbable polymer-based flow-diverting stent that gently redirects blood flow to facilitate the healing of weakened blood vessels. This advanced medical device is designed to minimize the need for invasive procedures, allowing physicians to efficiently and effectively treat patients while reducing the risk of stroke. Through its pioneering approach, Fluid Biomed is poised to contribute significantly to the field of neurosurgery and improve the quality of care for individuals with brain aneurysms.

Ikarovec is a gene therapy company focused on developing early-stage treatments for common eye diseases, particularly diabetic macular edema. The company aims to address multiple disease targets and pathways, working on therapies that also target dry-form age-related macular degeneration, neovascular (wet-form) age-related macular degeneration, and ocular hypertension. By advancing these innovative treatments, Ikarovec seeks to provide effective solutions for patients, helping to restore sight and prevent blindness.

Ozlo Sleep is a science-driven sleep and audio technology company that supports and simplifies sleep rituals for clinical benefits, without the use of medication.

Ozlo Sleep is a science-driven sleep and audio technology company that supports and simplifies sleep rituals for clinical benefits, without the use of medication.

Affect Therapeutics operates a digital platform delivering addiction treatment via a mobile app. Their program employs contingency management and rewards systems to encourage healthy behaviors and habits, aiming to improve patient outcomes for various substance use disorders.

Maxion Therapeutics is a biopharmaceutical company focused on developing innovative therapies for diseases driven by ion channels and G protein-coupled receptors (GPCRs). The company utilizes a unique drug discovery platform that integrates ion channel-modulating mini-proteins, known as knottins, derived from venom and other natural sources. By combining these knottins with antibody frameworks, Maxion aims to create long-acting, safe, and effective therapeutics that address previously inaccessible medical targets. This approach enables the potential treatment of various conditions, including chronic pain, autoimmune disorders, and heart disease, ultimately enhancing patient care through advanced drug development.

OXcan is a startup that focuses on early detection of lung cancer using advanced machine learning and liquid biopsy technologies. The company has developed an artificial intelligence-based healthcare platform that identifies cancer by analyzing targeted blood tests. This platform detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine screening. By evaluating multidimensional liquid biopsy results, which include DNA, proteins, epigenetic markers, and patient medical histories, OXcan enables healthcare providers to achieve early cancer detection and implement curative treatment strategies.

Cytospire Therapeutics specializes in developing a portfolio of innovative, next-generation immune cell engagers. These are multispecific antibodies designed to enhance and direct the power of key effector cells in the immune system, offering patients more effective treatments compared to existing therapies.

Surgery Hero is a pioneering digital prehabilitation clinic that focuses on preparing individuals for surgery and facilitating their recovery in the comfort of their homes. The company offers a digital care platform designed for surgery preparation, perioperative care, and post-operative recovery. By utilizing expert health coaches and providing digital guidance, Surgery Hero helps clients adopt lifestyle habits that are scientifically proven to enhance surgical outcomes. This approach not only optimizes both physical and mental readiness prior to surgery but also aims to reduce the risk of complications and accelerate the recovery process.

AviadoBio is a biotechnology company focused on developing transformative gene therapies for neurodegenerative disorders, specifically targeting diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages innovative research from King’s College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a deep understanding of brain biology with proprietary gene therapies, AviadoBio aims to effectively address the challenges of delivering treatments to the appropriate areas within the nervous system. The ultimate goal is to enhance the therapeutic potential of gene therapy, potentially halting or even reversing the progression of these debilitating conditions, thereby improving the quality of life for affected individuals.

Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, focused on creating innovative solutions that integrate prescription drugs with digital therapy. Founded by a team of healthcare professionals and scientists, the company aims to optimize drug dosing tailored to individual needs while incorporating linked behavioral therapy to enhance patient outcomes. Closed Loop Medicine is recognized as a leader in developing combination products that address chronic diseases, with current projects targeting hypertension and insomnia, among others. The company's approach emphasizes the importance of both patients and clinicians in the design and development of its offerings, ensuring that they meet real-world healthcare needs effectively.

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, that specializes in developing therapeutic drugs for hyperexcitability disorders affecting the nervous system. Founded in 2018, the company focuses on creating innovative treatments for conditions such as chronic pain, depression, epilepsy, and anxiety, which significantly impact millions of individuals. Eliem utilizes its expertise in neuroscience and translational medicine to advance a promising pipeline of drug candidates, including its lead candidate, ETX-155, aimed at addressing major depressive disorder and focal onset seizures. The company's mission centers on meeting unmet medical needs and improving patients' quality of life through its novel therapies.

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

DJS Antibodies Ltd is a biotechnology company based in Bicester, United Kingdom, established in 2014. The company focuses on the design and discovery of novel therapeutic monoclonal antibodies specifically targeting G-protein-coupled receptors (GPCRs). DJS Antibodies aims to develop innovative therapeutics for chronic inflammatory diseases by utilizing its advanced technology to create first-in-class antibody therapeutics for previously challenging disease targets. By specializing in the research and discovery of functional antibodies against complex protein targets that have eluded traditional drug discovery efforts, DJS Antibodies endeavors to provide effective treatments for diseases that are currently considered undruggable and untreatable.

BrainWaveBank, established in 2015, is a UK-based brain health research company. It specializes in developing data-centric solutions to track and understand cognitive health. The company's flagship product, also named BrainWaveBank, is a wearable EEG headset that measures brain activity while users engage in mobile games, enabling daily tracking of cognitive health at home. This data is securely stored and analyzed, creating neurocognitive profiles for individuals and populations, and aiding clinical professionals in advancing brain health research and treatments. The company has offices in Belfast, Northern Ireland, and Dublin, Ireland.

Brightlobe Limited, founded in 2012 and based in London, United Kingdom, specializes in creating tablet games aimed at supporting children's growth and development, particularly for those facing chronic illnesses. The company's innovative platform integrates gaming with healthcare, providing tools for early detection of pediatric conditions such as autism and ADHD, which is currently undergoing clinical trials in the US and UK. Brightlobe's team, composed of experts in game design, machine learning, and cognitive neuroscience, focuses on fostering collaboration among parents, teachers, and healthcare professionals to monitor and enhance a child's development. The platform is designed for educational purposes and does not provide medical advice, diagnosis, or treatment.

Vicore Pharma Holding is a clinical-stage pharmaceutical company that specializes in developing innovative treatments for severe lung disorders, particularly idiopathic pulmonary fibrosis (IPF). The company is advancing its lead drug candidate, C21, a small molecule angiotensin II type 2 receptor agonist, which is currently in phase 2a clinical development for IPF and has received orphan drug designation in both the EU and the US. In addition to C21, Vicore is exploring pre-clinical applications of the drug in other rare diseases associated with the AT2 receptor. The company is also developing Almee, a digital therapeutic that utilizes cognitive behavioral therapy to address the psychological challenges faced by patients with pulmonary fibrosis. Headquartered in Astra Zeneca’s Bioventurehub in Mölndal, Vicore Pharma aims to establish a comprehensive portfolio targeting respiratory diseases.

PolyProx Therapeutics Ltd is a biotechnology company based in Cambridge, United Kingdom, founded in 2018. It focuses on researching and developing innovative drug therapies aimed at treating cancer and neurodegenerative diseases. The company's flagship product, Polyproxin, utilizes engineered proteins that selectively target tumor cells. This mechanism activates the natural degradation processes within the cells, allowing for the removal of disease-causing proteins. By employing this novel approach, PolyProx aims to provide effective treatment options for cancer patients, potentially improving their outcomes and quality of life.

Ikarovec is a gene therapy company focused on developing early-stage treatments for common eye diseases, particularly diabetic macular edema. The company aims to address multiple disease targets and pathways, working on therapies that also target dry-form age-related macular degeneration, neovascular (wet-form) age-related macular degeneration, and ocular hypertension. By advancing these innovative treatments, Ikarovec seeks to provide effective solutions for patients, helping to restore sight and prevent blindness.

AviadoBio is a biotechnology company focused on developing transformative gene therapies for neurodegenerative disorders, specifically targeting diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages innovative research from King’s College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a deep understanding of brain biology with proprietary gene therapies, AviadoBio aims to effectively address the challenges of delivering treatments to the appropriate areas within the nervous system. The ultimate goal is to enhance the therapeutic potential of gene therapy, potentially halting or even reversing the progression of these debilitating conditions, thereby improving the quality of life for affected individuals.

Caldan Therapeutics Ltd is a biotechnology company formed as a spinout from the University of Glasgow and the University of Southern Denmark. The company is focused on developing innovative therapeutics that target free fatty acid receptors, which play a significant role in the pathophysiology of metabolic diseases such as Type 2 Diabetes (T2D). The collaboration between Professors Graeme Milligan and Trond Ulven has led to the identification of these receptors as promising targets for addressing various aspects of T2D, including insulin secretion, sensitivity, and cellular protection. In addition to T2D, Caldan Therapeutics is exploring the potential of its technology to treat other conditions, including non-alcoholic steatohepatitis (NASH) and inflammatory diseases.

SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases and cancer. Founded in 2017 and headquartered in Stamford, Connecticut, the company employs a precision medicine approach to create targeted oncology solutions. Its lead product candidate, nirogacestat, is an oral small molecule gamma secretase inhibitor currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing mirdametinib, an oral small molecule MEK inhibitor, which is undergoing Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas. The company is also exploring various combination therapies involving nirogacestat and mirdametinib for multiple myeloma and solid tumors. SpringWorks has established collaborations with notable organizations to enhance its research and development efforts, aiming to unlock new treatment options for underserved patient populations.

AMR Centre Limited, established in 2016 and headquartered in Macclesfield, UK, specializes in the development of novel antibiotics to combat antimicrobial resistance. The company offers its expertise and facilities to global pharmaceutical entities on a collaborative basis, with an agreement to share commercially in any successful new products resulting from these partnerships.

SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases and cancer. Founded in 2017 and headquartered in Stamford, Connecticut, the company employs a precision medicine approach to create targeted oncology solutions. Its lead product candidate, nirogacestat, is an oral small molecule gamma secretase inhibitor currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing mirdametinib, an oral small molecule MEK inhibitor, which is undergoing Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas. The company is also exploring various combination therapies involving nirogacestat and mirdametinib for multiple myeloma and solid tumors. SpringWorks has established collaborations with notable organizations to enhance its research and development efforts, aiming to unlock new treatment options for underserved patient populations.

GlycoEra is a biotechnology research company focused on developing innovative therapeutics that target significant unmet medical needs in inflammatory and autoimmune diseases, as well as in immune-oncology. The company has established a proprietary platform that enables the creation of first-in-class biologics by assembling customized and highly homogeneous human glycans onto glycoproteins in a site-specific manner. This approach facilitates a deeper understanding of the role of glycans in human health and disease, positioning GlycoEra to contribute meaningfully to the advancement of novel treatment options in the healthcare sector.